The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4155/tde-2017-0038 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!